![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Adial Pharmaceuticals Inc | NASDAQ:ADILW | NASDAQ | Equity Warrant |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0009 | 0.0007 | 0.0011 | 0 | 01:00:00 |
Event | 35th Annual Roth Conference |
Date | March 14, 2023 |
Presentation | 12:00 PM Pacific Time (3:00 PM Eastern Time) |
Webcast | https://wsw.com/webcast/roth46/adil/1802710 |
Location | Dana Point, CA |
The live audio webcast and replay will be available in the investor relations section of the Company’s website at www.adial.com/news-events/.
Mr. Claiborne will be available for one-on-one and small group investor meetings during the conference.
To arrange a 1-on-1 please email oneononerequests@roth.com, or contact your Roth sales team. For more information about the event or questions about registration, please contact your Roth representative.
About Adial Pharmaceuticals, Inc.Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Contact:Crescendo Communications, LLC David Waldman / Alexandra Schilt Tel: 212-671-1020 Email: adil@crescendo-ir.com
1 Year Adial Pharmaceuticals Chart |
1 Month Adial Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions